Biological therapies that include TNF-α inhibitors, such as infliximab, adalimumab, golimumab, and certolizumab pegol, are being effectively used to suppress excessive intestinal inflammation for inducing and maintaining remission in patients with IBD [28]. Here, TNF is linked to inflammatory bowel disease.